Albert Gris‐Oliver

Author

Albert Gris‐Oliver

Universitat Autònoma de Barcelona ORCID

Also Known As

A Gris-Oliver, A. Gris-Oliver, Albert Gris-Oliver, Albert Gris‐Oliver, Gris-Oliver, Albert

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

Universitat Autònoma de Barcelona Vall d'Hebron Institute of Oncology Institució Catalana de Recerca i Estudis Avançats Cancer Research UK Cambridge Center Centro de Investigación Biomédica en Red de Cáncer

About

Albert Gris‐Oliver is an author at Universitat Autònoma de Barcelona specializing in medicine, oncology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	275
2	Cell Biology	3	3	275
3	Pathology	1	1	19
4	Cell Signaling	1	1	18
5	Immunotherapy	1	1	19

Albert Gris‐Oliver

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer Cristina Cruz, Marta Castroviejo‐Bermejo, Sara Gutiérrez‐Enríquez, Annals of Oncology	2018	410
A <scp>RAD</scp> 51 assay feasible in routine tumor samples calls <scp>PARP</scp> inhibitor response beyond <scp>BRCA</scp> mutation Marta Castroviejo‐Bermejo, Cristina Cruz, Alba Llop‐Guevara, EMBO Molecular Medicine	2018	263
PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer Fara Brasó‐Maristany, Simone Filosto, Steven Catchpole, Nature Medicine Breast OncologyOncologyMedicineTumor GrowthPim1 Kinase	2016	238
TLR2 and TLR7 mediate distinct immunopathological and antiviral plasmacytoid dendritic cell responses to SARS‐CoV‐2 infection Renée M. van der Sluis, Lamin B. Cham, Albert Gris‐Oliver, The EMBO Journal	2022	97
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance Violeta Serra, Anderson T. Wang, Marta Castroviejo‐Bermejo, Clinical Cancer Research	2022	80
In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer Ivana Zagorac, Sara Fernandez-Gaitero, Renske Penning, Nature Communications	2018	55
Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts Albert Gris‐Oliver, Marta Palafox, Laia Monserrat, Clinical Cancer Research	2020	38
AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors Shanade Dunn, Cath Eberlein, Jason Yu, Oncogene	2022	30
MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by <i>TP53</i> Mutation in Preclinical Models of Colorectal Cancer Celina García-García, Martín A. Rivas, Yasir H. Ibrahim, Clinical Cancer Research	2015	23
Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns Lídia Mateo, Miquel Duran‐Frigola, Albert Gris‐Oliver, Genome Medicine	2020	22

Page 1